News for COMPASS Pathways plc (CMPS)

In a recent update, H.C. Wainwright has maintained a Buy rating for Compass Pathways (CMPS), emphasizing the favorable outcome of the Phase 3 COMP005 trial. Thi

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Tesla Inc. and Coinbase Global Inc. . These trades reflect Ark’s strategic positioning amid ongoing market developments.

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and market trends. Click for my CMPS update.

Psychedelic medicine industry faces setbacks with key clinical trial results. Significant stock movement observed in major players like Compass Pathways

On June 23, 2025, Compass Pathways (CMPS) received a significant analyst update from Evercore ISI Group, represented by analyst Josh Schimmer. The firm has down

Compass Pathways (CMPS) experienced a downgrade from Evercore ISI, moving from an "Outperform" to an "In Line" rating. The price target was also reduced to $6 f

After Compass Pathways (CMPS) disclosed the top-line results of its Phase 3 COMP005 trial, Stifel remarks that the 3.6 point difference in MADRS scores between

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.02% to 42,216.40 while...

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Monday. Following the market opening Monday, the Dow traded up 0.50...

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday. Shares of Vizsla Silver Corp. VZLA fell sharply in today's p...

Compass Pathways (CMPS) achieves primary endpoint in Phase 3 trial for COMP360 psilocybin treating treatment-resistant depression (TRD). COMP360 demonst

Shares of Sequans Communications S.A. SQNS rose sharply in today's pre-market trading after the company announced a $384 million strategic investment to launch ...

Mary-Elizabeth Gifford, Psyence BioMed's (PBM) Chief of Global Impact, will speak at the Psychedelic Science 2025 conference. The event, hosted by MAPS,

U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday. Shares of Agilysys, Inc. AGYS rose sharply during Tuesday's session f...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is enteri

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced

On December 31, 2024, Citadel Advisors LLC (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Compass Pathways PL